HOME >> BIOLOGY >> NEWS
New advances in thrombosis help further understanding of disease prevention

eemed to experience a higher incidence of major bleeding over that of standard therapy (0.7 percent - 25 mg bid; 4.1 percent - 50 mg bid; 3.5 percent - 75 mg bid; and 5.8 percent - 100 mg bid versus 0.0 percent - enoxaparin 30 mg bid). The three highest doses of razaxaban were stopped before the intended sample size of 150 patients was reached, due to increased reports of bleeding. In this study, the lowest dose of razaxaban, 25 mg bid, demonstrated potential for increased efficacy and similar safety compared to current standard treatment.

Randomized, Double-Blind Comparison of Ximelagatran, an Oral Direct Thrombin Inhibitor, and Warfarin to Prevent Venous Thromboembolism (VTE) after Total Knee Replacement (TKR): EXULT B (Abstract 39)

Total knee replacement surgery, like many other major orthopedic surgeries, continues to be hampered by venous thromboembolism events, such as deep vein thrombosis and pulmonary embolism. Without any preventive medication, harmful blood clots occur in two thirds of all total knee replacement surgery patients. Anticoagulants that are currently approved in the U.S. for prevention of venous thromboembolism are still associated with unacceptably high rates of deep vein thrombosis and require regular dosage monitoring to prevent major bleeding events.

"Oral anticoagulants that are currently available have many limitations. There is a great need for new therapies with increased safety and efficacy," said Charles Francis, M.D., of the University of Rochester, Rochester, N.Y., lead investigator of the study. "The results from this study encourage us to continue looking at ximelagatran as a preventive treatment for this serious complication in total knee replacement surgery."

The trial, led by Dr. Francis, compares the safety and efficacy of ximelagatran, a novel oral direct thrombin inhibitor, to warfarin for prevention of venous thromboembolism in total knee replacement patients.
'"/>

Contact: Aimee Frank
amf@spectrumscience.com
202-955-6222
American Society of Hematology
6-Dec-2003


Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Grant advances biochemical engineering laboratory
2. Virginia Bioinformatics Institute researcher advances fight against sudden oak death disease
3. Undergraduate research experience advances education
4. UT Southwestern researchers cite recent advances in underlying causes of rare body-fat disorders
5. UCSF finding advances insight into adult stem cells in human brain
6. Federal grant supports advances in infant heart disease at Childrens Hospital of Philadelphia
7. Human embryonic stem cells may promise medical advances
8. Scientists making advances in cancer prevention, detection and treatment to receive awards
9. Conference to highlight medical advances resulting from 50 years of DNA knowledge
10. Annual bibliography of significant advances in dietary supplement research 2002
11. Dartmouth study advances prion disease research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2016)... , Feb. 2, 2016   Parabon ... from the U.S. Army Research Office and the ... range and sensitivity of the company,s Snapshot ... Accounting Mission and, more generally, defense-related DNA forensics. ... phenotyping capabilities (predicting appearance and ancestry from DNA ...
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
(Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical solutions ... of the Steering Committee for its Pelvic Mass Registry. ... Pelvic masses can present physicians and healthcare professionals with ... ruled out, pelvic masses may include cancers of the ... tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... Feb. 11, 2016  Wellcentive today announced it ... Portland, Oregon -based community care organization (CCO) ... health analytics, quality reporting and care management solutions ... its team of quality managers, analysts and care ... provider groups serving FamilyCare members. ...
(Date:2/11/2016)... , Feb. 11, 2016   BioInformant ... report, "Stem Cell Research Products, Opportunities, Tools, and Technologies ... ... in the stem cell industry, BioInformant has more than ... the stem cell market, by stem cell type. This ...
(Date:2/10/2016)... 2016 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... that Mitsui & Co. Ltd., its partner in the ... is investing an additional CDN$25 million in the joint ... from 30% to 40%.  Mitsui will also play a ... in Sarnia , providing dedicated resources ...
Breaking Biology Technology:
Cached News: